

Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. and its subsidiaries Avrio Health L.P. and Adlon Therapeutics L.P.

Purdue Pharma L.P. and its subsidiaries Avrio Health L.P. and Adlon Therapeutics L.P. (“Purdue”) has recalculated its 340B ceiling prices for the period Q4 2017 for various products, and performed a true up analysis for the newly marketed Adhansia XR capsules ® (Methylphenidate Hydrochloride) for Q3 2019 and Q4 2019. Products whose ceiling price were impacted by revisions to their Medicaid pricing data and where purchases existed are listed below. Also listed are the relevant 340B ceiling price quarters for which the ceiling price of that product was impacted. Purdue has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the HRSA public website to ensure transparency by providing access to information about Purdue’s recalculation affecting certain 340B Covered Entities for the impacted Purdue product.

Purdue has determined the credit amount owed to each affected covered entity. Purdue will be working with Apexus, LLC (“Apexus”), the 340B Prime Vendor, to validate wholesaler pharmacy account information for each affected Covered Entity. If a wholesaler account is identified, Purdue will issue a credit to the Covered Entity through the wholesaler, and a check will be issued to Covered Entities whose wholesaler account cannot be identified. If a Covered Entity believes they are due a refund and are not contacted by Apexus within a month after the posting of this notice, you may contact Alicia Graziano, Purdue Pharma L.P. Director of Government and Institutional Contract Ops, at Alicia.Graziano@pharma.com.

<u>Product NDC</u>	<u>Product Description</u>	<u>Relevant Period</u>
59011025530	Intermezzo 3.5 mg sublingual tablets (30 unit-dose pouches/carton)	Q4 2017
59011025630	Intermezzo 1.75 mg sublingual tablets (30 unit-dose pouches/carton)	Q4 2017
59011075004	Butrans 5 mcg/hour Transdermal System (4 systems/carton)	Q4 2017
59011075704	Butrans 7.5 mcg/hour Transdermal System	Q4 2017
59011075104	Butrans 10 mcg/hour Transdermal System (4 systems/carton)	Q4 2017
59011075804	Butrans 15 mcg/hour Transdermal System (4 systems/carton)	Q4 2017
59011075204	Butrans 20 mcg/hour Transdermal System (4 systems/carton)	Q4 2017
72912052530	Adhansia XR 25mg Capsules, 60’s	Q3 / Q4 2019
72912053530	Adhansia XR 35mg Capsules, 60’s	Q3 / Q4 2019
72912054530	Adhansia XR 45mg Capsules, 60’s	Q3 / Q4 2019
72912055530	Adhansia XR 55mg Capsules, 60’s	Q3 / Q4 2019
72912057030	Adhansia XR 70mg Capsules, 60’s	Q3 / Q4 2019
72912058530	Adhansia XR 85mg Capsules, 60’s	Q3 / Q4 2019